Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Analysis of provider specialties in the treatment of patients with clinically diagnosed back and joint problems.

Wilson FA, Licciardone JC, Kearns CM, Akuoko M.

J Eval Clin Pract. 2015 Oct;21(5):952-7. doi: 10.1111/jep.12411. Epub 2015 Jul 7.

PMID:
26154344
2.

Somatic dysfunction and use of osteopathic manual treatment techniques during ambulatory medical care visits: a CONCORD-PBRN study.

Licciardone JC, Kearns CM, King HH, Seffinger MA, Crow WT, Zajac P, Devine WH, Abu-Sbaih RY, Miller SJ, Berkowitz MR, Dyer R, Heath DM, Treffer KD, Nevins NA, Aryal S.

J Am Osteopath Assoc. 2014 May;114(5):344-54. doi: 10.7556/jaoa.2014.072.

PMID:
24777999
3.

Changes in biomechanical dysfunction and low back pain reduction with osteopathic manual treatment: results from the OSTEOPATHIC Trial.

Licciardone JC, Kearns CM, Crow WT.

Man Ther. 2014 Aug;19(4):324-30. doi: 10.1016/j.math.2014.03.004. Epub 2014 Mar 18.

4.

Outcomes of osteopathic manual treatment for chronic low back pain according to baseline pain severity: results from the OSTEOPATHIC Trial.

Licciardone JC, Kearns CM, Minotti DE.

Man Ther. 2013 Dec;18(6):533-40. doi: 10.1016/j.math.2013.05.006. Epub 2013 Jun 10.

5.

Osteopathic manual treatment in patients with diabetes mellitus and comorbid chronic low back pain: subgroup results from the OSTEOPATHIC Trial.

Licciardone JC, Kearns CM, Hodge LM, Minotti DE.

J Am Osteopath Assoc. 2013 Jun;113(6):468-78.

PMID:
23739758
6.

Osteopathic manual treatment and ultrasound therapy for chronic low back pain: a randomized controlled trial.

Licciardone JC, Minotti DE, Gatchel RJ, Kearns CM, Singh KP.

Ann Fam Med. 2013 Mar-Apr;11(2):122-9. doi: 10.1370/afm.1468.

7.

Depression, somatization, and somatic dysfunction in patients with nonspecific chronic low back pain: results from the OSTEOPATHIC Trial.

Licciardone JC, Gatchel RJ, Kearns CM, Minotti DE.

J Am Osteopath Assoc. 2012 Dec;112(12):783-91.

PMID:
23212429
9.

A new triadic paradigm for osteopathic research in real-world settings.

Licciardone JC, Kearns CM.

J Am Osteopath Assoc. 2012 Jul;112(7):447-56.

PMID:
22802545
11.

Background and methodology of the Osteopathic Survey of Health Care in America 2010 (OSTEOSURV 2010).

Licciardone JC, Kearns CM, Ruggiere P.

J Am Osteopath Assoc. 2011 Dec;111(12):670-84.

PMID:
22182953
12.

The osteopathic research center will remain key to osteopathic medical profession.

Licciardone JC, King HH, Kearns CM.

J Am Osteopath Assoc. 2008 Jul;108(7):353-5. No abstract available.

PMID:
18648032
13.

Eureka--implementing safe community needle disposal in Rhode Island.

Caranci PF, Farmanian R, Goldman D, Kearns CM, LeBoeuf K, Nicholson R, Sands R, Scheraga M.

J Am Pharm Assoc (Wash). 2002 Nov-Dec;42(6 Suppl 2):S109-10. No abstract available.

PMID:
12489629
14.

Temporal dispersal: ecological and evolutionary aspects of zooplankton egg banks and the role of sediment mixing.

Hairston NG Jr, Kearns CM.

Integr Comp Biol. 2002 Jul;42(3):481-91. doi: 10.1093/icb/42.3.481.

PMID:
21708742
15.

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer.

Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ.

J Clin Oncol. 1999 Feb;17(2):676-84.

PMID:
10080614
16.

THE ROLES OF FLUCTUATING SELECTION AND LONG-TERM DIAPAUSE IN MICROEVOLUTION OF DIAPAUSE TIMING IN A FRESHWATER COPEPOD.

Ellner SP, Hairston NG Jr, Kearns CM, Babaï D.

Evolution. 1999 Feb;53(1):111-122. doi: 10.1111/j.1558-5646.1999.tb05337.x.

PMID:
28565171
17.

Evaluation of the linearity of docetaxel pharmacokinetics.

McLeod HL, Kearns CM, Kuhn JG, Bruno R.

Cancer Chemother Pharmacol. 1998;42(2):155-9.

PMID:
9654116
18.

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL.

J Clin Oncol. 1998 May;16(5):1811-9.

PMID:
9586895
19.

Pharmacokinetics of the taxanes.

Kearns CM.

Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):105S-109S. Review.

PMID:
9322877
20.

Current issues in chemotherapy: the taxanes, platinum compounds, and oxazaphophorines: introduction.

Kearns CM.

Pharmacotherapy. 1997 Sep-Oct;17(5 Pt 2):93S-95S. No abstract available.

PMID:
9322875
21.

GDNF protection against 6-OHDA: time dependence and requirement for protein synthesis.

Kearns CM, Cass WA, Smoot K, Kryscio R, Gash DM.

J Neurosci. 1997 Sep 15;17(18):7111-8.

22.
23.

Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response.

Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF.

Semin Oncol. 1996 Dec;23(6 Suppl 16):128-35.

PMID:
9007140
24.

Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas.

Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E, Egorin MJ.

J Clin Oncol. 1996 Feb;14(2):600-9.

PMID:
8636777
25.

Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii.

Egorin MJ, Sentz DL, Rosen DM, Ballesteros MF, Kearns CM, Callery PS, Eiseman JL.

Cancer Chemother Pharmacol. 1996;39(1-2):51-60.

PMID:
8995499
26.

Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions.

Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ.

Semin Oncol. 1995 Oct;22(5 Suppl 12):26-32.

PMID:
7481858
27.

Pharmacokinetics of paclitaxel and carboplatin in combination.

Kearns CM, Belani CP, Erkmen K, Zuhowski M, Hiponia D, Zacharski D, Engstrom C, Ramanathan R, Trenn MR, Aisner J, et al.

Semin Oncol. 1995 Oct;22(5 Suppl 12):1-4; discussion 5-7.

PMID:
7481850
28.

The Interaction of Photoperiod and Temperature in Diapause Timing: A Copepod Example.

Hairston NG Jr, Kearns CM.

Biol Bull. 1995 Aug;189(1):42-48. doi: 10.2307/1542200.

PMID:
29281421
29.

Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors.

Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P, Egorin MJ.

J Natl Cancer Inst. 1995 Jul 19;87(14):1077-81.

PMID:
7616600
30.

Paclitaxel pharmacokinetics and pharmacodynamics.

Kearns CM, Gianni L, Egorin MJ.

Semin Oncol. 1995 Jun;22(3 Suppl 6):16-23. Review.

PMID:
7597430
31.

GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

Kearns CM, Gash DM.

Brain Res. 1995 Feb 20;672(1-2):104-11.

PMID:
7749731
32.

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

Gianni L, Kearns CM, Giani A, Capri G, Vigan├│ L, Lacatelli A, Bonadonna G, Egorin MJ.

J Clin Oncol. 1995 Jan;13(1):180-90.

PMID:
7799018
33.

Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.

Kearns CM, Blakley RL, Santana VM, Crom WR.

Cancer Res. 1994 Mar 1;54(5):1235-9.

34.

Splenosis presenting as a left renal mass: a report of two cases.

Kearns CM, Liu HY, Wollin M, Lepor H.

Eur Urol. 1994;26(3):264-6.

PMID:
7805715
35.

Disposition of recombinant human granulocyte colony-stimulating factor in children with severe chronic neutropenia.

Kearns CM, Wang WC, Stute N, Ihle JN, Evans WE.

J Pediatr. 1993 Sep;123(3):471-9.

PMID:
7689097
36.

Development and testing of second generation extracorporeal shock-wave lithotriptor.

Begun FP, Lawson RK, Cauley JE, Kearns CM, Foley D, Middelton WD.

Urology. 1990 Sep;36(3):237-44.

PMID:
2203197
37.

Electrohydraulic shock wave induced renal injury.

Begun FP, Lawson RK, Kearns CM, Tieu TM.

J Urol. 1989 Jul;142(1):155-9.

PMID:
2733096

Supplemental Content

Loading ...
Support Center